Built by the people who know hydrogen best

Seven years. Two scientists. Zero Shortcuts.

CEO

Alex Tarnava

Inventor of the hydrogen tablet — the most widely used form of supplemental hydrogen in the world. He spent seven years building InhaleH2  because anything less would be scientifically unethical.

THE RESEARCHER

Dr. Tyler LeBaron

Founder of the Molecular Hydrogen Institute. The world’s foremost hydrogen researcher. He doesn’t endorse products. He evaluates mechanisms. He waited 16 years to find one worth endorsing.

A Shared Mission

InhaleH2 was born from a shared mission to make hydrogen inhalation safe, effective, and accessible. In 2018, Tyler W. LeBaron, MSc, PhD, and Alex Tarnava (inventor of the open-cup H₂-producing tablets) were discussing the growing body of research on hydrogen water and hydrogen gas inhalation.

This conversation led to concerns about the inhalation devices available on the market. Most units delivered hydrogen at flow rates either so low they were unlikely to offer any therapeutic benefits, or high enough to be potentially therapeutic, but also flammable and explosive. As a result, many clinics, hospitals, and research institutions were unable to safely explore hydrogen inhalation therapy in research or for wellness initiatives.

Aligned Goals and an Engineering Challenge

The more they spoke, the more they realized their goals aligned:
  • to create a device that safely delivers hydrogen gas
  • ensure every inhaled breath achieves a precise concentration, regardless of body size or breathing pattern

Alex committed to building a machine that would bring this shared vision to life, and he asked Dr. LeBaron to consult on the project. The journey that followed was long and challenging. Despite years of collaboration with top-tier manufacturing partners, none of them were able to fully grasp the innovation behind the design, preferring to push their existing models. Others resisted a disruptive concept that challenged the status quo.

Overwhelmingly Positive Response

After multiple failed prototypes—with each iteration bringing greater clarity—a viable alpha unit was finally achieved, followed by a successful beta model.

Beta units were unveiled at the Health Optimization Summit in Austin, TX. The response was overwhelmingly positive. Six weeks of field testing confirmed the machine consistently delivered a safe, precise, and effective hydrogen concentration. Feedback from beta users led to further refinement, improving both the user experience and overall usability.

Hard-earned Endorsement

Now, after seven years of development—and for the first time in over 16 years—Dr. LeBaron has officially endorsed a hydrogen product, and has chosen to serve as the Chief Scientific Officer for InhaleH2 While he remains committed to his research, his leadership at MHI, and his independent advisory roles, this marks a milestone with Dr. LeBaron’s first public endorsement of a specific hydrogen technology.